Chronic Migraine

Oral Nurtec ODT 75 mg taken every other day effectively prevented migraines, according to results of a randomized, double-blind, placebo-controlled trial presented at the American Headache Society Virtual Annual Scientific Meeting.

Cannabis use ”significantly contributes” to the prevalence of medication overuse headache among patients with chronic migraine, according to study results scheduled for presentation at the American Academy of Neurology Annual Meeting.

The FDA has expanded the approval of a remote electrical neuromodulation device to treat episodic and chronic migraine in children aged 12 years and older, according to a press release issued by the manufacturer.

The FDA has expanded the approval for Nerivio, a wearable remote electrical neuromodulation device controlled by a smartphone app, to treat chronic migraine in adults aged 18 years and older.

In the phase 3 MOMENTUM and INTERCEPT trials, the investigational migraine drug AXS-07 met its coprimary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours compared with placebo.

A study presented at this year’s virtual PAINWeek meeting further demonstrated the safety and efficacy of remote electrical neuromodulation in reliving chronic migraine pain.

Galcanezumab was more effective than placebo in preventing migraine among patients with treatment-resistant migraine who also had other pain disorders, according to research presented at this year’s virtual PAINWeek.

Ubrogepant provided pain relief to patients with migraine in a real-world setting, according to preliminary results of an ongoing study evaluating recently approved treatments.

Treating patients who have chronic migraine with both onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibody medications could reduce their monthly migraine days by an additional 5.6 days than if they had just received onabotulinumtoxinA alone, according to research presented at the American Headache Society Annual Meeting.

Fewer than one in five patients with migraine who have 4 headache days or more each month go through the steps needed to receive preventive treatment, according to results from the OVERCOME study presented at the American Headache Society’s Annual Meeting.